Text Size

Ontogeny of Measles Immunity in Infants

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2009 by Stanford University.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT00240916
First received: October 14, 2005
Last updated: November 5, 2009
Last verified: November 2009
History of Changes
  Purpose

This is an immunogenicity study evaluating the development of the immune response of healthy infants following primary vaccination with Attenuvax at 6 or 9 months of age compared with responses in 12 month-old infants receiving MMR-II. Responses of infants receiving an early two dose measles vaccine regimen with the first dose given at 6 or 9 months followed by a second dose administered at 12 months will also be compared to infants given a single dose at 12 months of age (Table 2). The current approved regimen for measles vaccination is a first vaccination at 12-15 months and a subsequent vaccination at school entry.

A secondary endpoint of this study will be to assess the safety of measles vaccine administered as Attenuvax at 6 or 9 months of age and in an early two dose measles vaccine regimen with Attenuvax administered at 6 or 9 months followed by MMR-II at 12 months of age.


Condition Intervention
Measles
 Biological: Attenuvax (Measles Virus Live Vaccine, 0.5ml subcutaneous)
Biological: MMR-II (Measles-Mumps-Rubella Virus Live Vaccine, 0.5ml subcutaneous)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Ontogeny of Vaccine-Induced Measles Immunity Child Participant-6 and 9 Months

Resource links provided by NLM:

MedlinePlus related topics: Measles
U.S. FDA Resources

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Immune response to measles vaccine [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Affect of maternal antibodies on immune response to measles vaccine. [ Time Frame: 6 mo ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

white cells, serum


Estimated Enrollment: 555
Study Start Date: July 1993
Estimated Study Completion Date: July 2010
Estimated Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Detailed Description:

This is an open-label immunogenicity and safety study of live attenuated Measles Vaccine (Attenuvax) and Measles-Mumps-Rubella (MMR-II) vaccine administered to healthy children at 6 (n=70), 9 (n=70), or 12 (n=70) months of age. Attenuvax (Measles Virus Vaccine Live, Merck & Co., Inc) and MMR-II (Measles-Mumps-Rubella Virus Vaccine Live, Merck & Co., Inc) will be delivered as 0.5 mL per dose, administered subcutaneously. Both vaccines are licensed for use in infants in the United States. MMR-II is recommended as part of the childhood immunization schedule by the AAP and ACIP, and Attenuvax is recommended for use as a single component vaccine in infants 6-11 months particularly for foreign travel and in measles outbreaks79. Infants vaccinated with Attenuvax at 6 or 9 months receive MMR-II at 12 months of age as recommended for follow-up vaccination. Immunization against measles is given as a trivalent formulation with mumps and rubella and is indicated as a primary dose at 12-15 months of age with a second dose recommended routinely at time of school entry, 4-6 years of age, but can be given at any earlier age provided that the interval between the first and second doses is at least 4 weeks .

Two hundred and ten healthy children attending the Palo Alto Medical Clinic will be recruited into one of three cohorts over a five year period. (Table 1). All children in cohort 1 and 2 (6 and 9 month old infants) will receive Attenuvax as part of their participation in this study followed by MMR-II at 12 months of age as part of their routine WCC and not as a study vaccine. Infants recruited into cohort 3, (twelve month old infants) will receive one dose of MMR-II at 12 months. All infants in the study (cohort 1, 2 or 3) are receiving MMR-II at 12 months as part of their routine childhood vaccines. The vaccination schedules is summarized in Table 1. Other immunizations as required for routine WCC will be administered simultaneously. Participation will entail 2-4 visits, 2-3 blood samples, and 1-2 immunizations and will end after the 9-18 month visit, totaling 3 to 12 months time of participation for a subject depending on cohort and if participants opt for a second follow-up blood sample.

  Eligibility

Ages Eligible for Study:   6 Months and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Study populations include infants who are 6, 9, and 12 months of age, and healthy adults older than 18 years.

Criteria

Inclusion Criteria:Subjects must meet all of the following criteria in order to be enrolled:

  1. Healthy infants 6, 9, or 12 months (+ 3 weeks) of age
  2. Free of obvious health problems as established by medical history and clinical examination before entering into the study
  3. Parent/legal guardian willing and capable of signing written informed consent
  4. Parent/legal guardian expected to be available for entire study
  5. Parent/legal guardian can be reached by telephone

Exclusion Criteria:All subjects meeting any of the following exclusion criteria at baseline will be excluded from study participation:

  1. Former premature infants (<36 weeks)
  2. Birth weight < 2500grams
  3. Significant underlying chronic illness
  4. Immunodeficiency disease or immunosuppressive therapy in the participant
  5. Any other condition which in the clinical judgment of the investigator might interfere with vaccine evaluation
  6. Allergy to any components of the vaccine, including anaphylaxis or anyphalaxoid reaction to neomycin or eggs
  7. Administration of an investigational drug
  8. Blood products within 3 months of initial enrollment
  9. Current febrile respiratory illness or other active febrile infection
  10. Family history of congenital/hereditary immunodeficiency, unless immune competence of subject has been determined.
  11. Blood dyscrasias, leukemia, lymphomas of any type or other malignant neoplasms affecting the bone marrow or lymphatic systems.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00240916

Contacts
Contact: Ross DeHovitz, MD (650) 853-6022 rdehovitz@pamf.org

Locations
United States, California
Palo Alto Medical Foundation/Department of Pediatrics Recruiting
Palo Alto, California, United States, 94301
Contact: Ross DeHovitz, MD     650-853-6022     rdehovitz@pamf.org    
Sub-Investigator: Ross DeHovitz            
Stanford University School of Medicine Recruiting
Stanford, California, United States, 94305
Contact: Hayley Gans, MD     650-723-5682     hagans@stanford.edu    
Sub-Investigator: Ann Margaret Arvin            
Principal Investigator: Hayley Altman Gans            
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Hayley Altman Gans Stanford University
  More Information

No publications provided

Responsible Party: Hayley Altman Gans, Stanford University School of Medicine
ClinicalTrials.gov Identifier: NCT00240916     History of Changes
Other Study ID Numbers: SU-11142008-1344, DMID Protocol #05-0039
Study First Received: October 14, 2005
Last Updated: November 5, 2009
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Measles
Morbillivirus Infections
Paramyxoviridae Infections
 Mononegavirales Infections
RNA Virus Infections
Virus Diseases

ClinicalTrials.gov processed this record on May 16, 2013